Benjamin R. Oshrine
Expertise in
7
conditions

Dr. Benjamin R. Oshrine

Pediatric Hematology Oncology
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
Saint Petersburg, FL 
Clinical Trials:Currently Recruiting for 4 Trials

Expertise in
7
conditions
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
Saint Petersburg, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Oshrine specializes in blood and marrow transplants as a pediatric hematologist/oncologist in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. His clinical focus is in the treatment of high-risk leukemias with blood and marrow transplantation, and his research focus is in immune recovery after transplant. He joined the hospital in 2014 after completing a fellowship in pediatric hematology/oncology at the Children’s Hospital of Philadelphia. He received the Excellence in Service & Professionalism Award in the 2018 Johns Hopkins Medicine Clinical Excellence Awards.

Dr. Oshrine is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Severe Combined Immunodeficiency (SCID), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Gastrostomy.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Boston Children's Hospital, Pediatrics, 2011
Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in FL
Board Certifications
American Board Of Pediatrics
Fellowships
Children's Hospital of Philadelphia, Pediatric Hematology-Oncology, 2014
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
View 5 Less Insurance Carriers -

Locations

Johns Hopkins All Children's Outpatient Care, St. Petersburg
Suite 320, Saint Petersburg, FL 33701
Call: 727-767-4176

Additional Areas of Focus

Dr. Oshrine has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 11, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cyclophosphamide, Fludarabine, Melphalan, Tacrolimus
Study Phase: Phase 2
Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas
Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas
Enrollment Status: Recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Procedure, Other, Biological
Study Drugs: Lactobacillus Plantarum Strain 299, Lactobacillus Plantarum Strain 299v
Study Phase: Phase 3
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drugs: Vorinostat, Azacitidine Injection
Study Phase: Phase 1
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
View 9 Less Clinical Trials

40 Total Publications

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.
Journal: Blood advances
Published: March 24, 2023
View All 40 Publications
Similar Doctors
Irmel A. Ayala
Experienced in Immune Thrombocytopenic Purpura (ITP)
Dr. Irmel A. Ayala
Pediatric Hematology Oncology
Experienced in Immune Thrombocytopenic Purpura (ITP)
Dr. Irmel A. Ayala
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 700, Suite 7, Suite 700, Suite 7, 
Saint Petersburg, FL 
 (0.7 miles away)
727-767-8336
Languages Spoken:
English, Spanish
See accepted insurances

Dr. Ayala is the director of the Hemophilia and Bleeding Disorders Treatment Center at Johns Hopkins All Children's Hospital. She also is the hematology leader of the Young Women Bleeding Disorders/Menorrhagia Clinic, which focuses on a multidisciplinary approach to bleeding symptoms in girls and young women. Dr. Ayala also is involved in the Immune Dysregulation Clinic, which evaluates patients with autoimmune cytopenias in a multidisciplinary approach. Dr. Ayala joined the hospital in 2000. She was the chair of the Division of Hematology/Oncology between 2013-2017 and also served as interim director for the division between 2015-2016. Dr. Ayala's research experience includes multicenter national and international projects. Dr. Ayala received her medical degree from the University of Puerto Rico School of Medicine, her residency training at the San Juan City Hospital in Puerto Rico and her fellowship training at the Emory University School of Medicine Division of Pediatric Hematology/Oncology. Dr. Ayala is a member of the American Society of Pediatric Hematology/Oncology and the Hemophilia and Thrombosis Research Society. Dr. Ayala is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Hemophilia A, Venous Thromboembolism (VTE), Blood Clots, and Evans Syndrome.

Jonathan Metts
Dr. Jonathan Metts
Pediatric Hematology Oncology
Dr. Jonathan Metts
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
 (0.7 miles away)
727-767-4176
Languages Spoken:
English
See accepted insurances

Dr. Metts specializes in pediatric hematology/oncology in the Johns Hopkins All Children's Cancer & Blood Disorders Institute. He sees patients on our main campus in St. Petersburg and at the Johns Hopkins All Children’s Outpatient Care Center in Tampa. He joined the hospital in 2016. He received his medical degree from the University of South Carolina School of Medicine and completed an internship and residency in pediatrics at Johns Hopkins All Children’s Hospital through the University of South Florida Morsani School of Medicine. Dr. Metts then trained at Emory University School of Medicine as a pediatric hematology/oncology fellow. His clinical interests include sarcomas, rare solid tumors, and Phase 1 and Phase 2 trials for pediatric solid tumors. Dr. Metts is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Adult Soft Tissue Sarcoma.

Jennifer L. Mayer
Dr. Jennifer L. Mayer
Pediatric Hematology Oncology
Dr. Jennifer L. Mayer
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
 (0.7 miles away)
727-767-4176
Languages Spoken:
English
See accepted insurances

Dr. Mayer is a pediatric hematologist-oncologist in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. She specializes in the diagnosis and management of patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Hodgkin lymphoma and non-Hodgkin lymphoma. She is also the medical director of the Vascular Anomalies and Birthmarks Program at the hospital. She cares for patients with benign and aggressive vascular tumors, lymphatic and venous malformations, and overgrowth syndromes. She was named the William A. Baumgartner Physician of the Year for Johns Hopkins All Children's in the 2024 Johns Hopkins Medicine Clinical Awards. She previously received the hospital’s Best Consulting Physician Award in 2017. Dr. Mayer is the author of more than 30 publications and two textbook chapters. She has presented over 22 research abstracts at national and international medical conferences. She is program director of a three-year fellowship training program in pediatric hematology-oncology on the St. Petersburg, Florida, campus. Dr. Mayer joined Johns Hopkins All Children’s in 1996. Dr. Mayer received her medical degree with honors from Dartmouth Medical School in New Hampshire. She completed her pediatric residency, hematology-oncology fellowship, and clinical research fellowship at Yale University School of Medicine in Connecticut. She is a fellow of the American Academy of Pediatrics and an active member and clinical researcher with Children’s Oncology Group, American Society of Pediatric Hematology-Oncology, and the International Society for the Study of Vascular Anomalies. Dr. Mayer is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Evans Syndrome, Acute Monoblastic Leukemia (AmoL), and Teratoma of the Mediastinum.

VIEW MORE IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oshrine's expertise for a condition
ConditionClose
    • Distinguished
    • Chronic Graft Versus Host Disease (cGvHD)
      Dr. Oshrine is
      Distinguished
      . Learn about Chronic Graft Versus Host Disease (cGvHD).
      See more Chronic Graft Versus Host Disease (cGvHD) experts
    • Advanced
    • Bone Marrow Transplant
      Dr. Oshrine is
      Advanced
      . Learn about Bone Marrow Transplant.
      See more Bone Marrow Transplant experts
    • Graft Versus Host Disease (GvHD)
      Dr. Oshrine is
      Advanced
      . Learn about Graft Versus Host Disease (GvHD).
      See more Graft Versus Host Disease (GvHD) experts
    • Juvenile Myelomonocytic Leukemia (JMML)
      Dr. Oshrine is
      Advanced
      . Learn about Juvenile Myelomonocytic Leukemia (JMML).
      See more Juvenile Myelomonocytic Leukemia (JMML) experts
    • Leukemia
      Dr. Oshrine is
      Advanced
      . Learn about Leukemia.
      See more Leukemia experts
    • Severe Combined Immunodeficiency (SCID)
      Dr. Oshrine is
      Advanced
      . Learn about Severe Combined Immunodeficiency (SCID).
      See more Severe Combined Immunodeficiency (SCID) experts
    • X-Linked Severe Combined Immunodeficiency
      Dr. Oshrine is
      Advanced
      . Learn about X-Linked Severe Combined Immunodeficiency.
      See more X-Linked Severe Combined Immunodeficiency experts
    • Experienced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Oshrine is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Chronic Granulomatous Disease
      Dr. Oshrine is
      Experienced
      . Learn about Chronic Granulomatous Disease.
      See more Chronic Granulomatous Disease experts
    • Congenital Athymia
      Dr. Oshrine is
      Experienced
      . Learn about Congenital Athymia.
      See more Congenital Athymia experts
    • Gastrostomy
      Dr. Oshrine is
      Experienced
      . Learn about Gastrostomy.
      See more Gastrostomy experts
    • Infantile Neutropenia
      Dr. Oshrine is
      Experienced
      . Learn about Infantile Neutropenia.
      See more Infantile Neutropenia experts
    • Omenn Syndrome
      Dr. Oshrine is
      Experienced
      . Learn about Omenn Syndrome.
      See more Omenn Syndrome experts
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.